Orbimed Advisors LLC Increases Stock Position in Dyne Therapeutics, Inc. $DYN

Orbimed Advisors LLC increased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 32.5% during the first quarter, HoldingsChannel.com reports. The fund owned 2,917,884 shares of the company’s stock after buying an additional 715,700 shares during the period. Dyne Therapeutics makes up approximately 1.0% of Orbimed Advisors LLC’s holdings, making the stock its 29th largest holding. Orbimed Advisors LLC’s holdings in Dyne Therapeutics were worth $52,901,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics during the 1st quarter worth $26,000. Strs Ohio acquired a new position in Dyne Therapeutics in the fourth quarter valued at $51,000. Aster Capital Management DIFC Ltd purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at about $84,000. Steward Partners Investment Advisory LLC raised its holdings in shares of Dyne Therapeutics by 102.1% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of Dyne Therapeutics by 275.1% during the second quarter. Tower Research Capital LLC TRC now owns 10,495 shares of the company’s stock worth $100,000 after buying an additional 7,697 shares during the period. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on DYN shares. Sanford C. Bernstein boosted their price target on Dyne Therapeutics from $23.00 to $24.00 and gave the company a “market perform” rating in a research report on Wednesday, May 13th. Wall Street Zen raised Dyne Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, July 6th. TD Cowen began coverage on shares of Dyne Therapeutics in a research report on Friday, June 26th. They issued a “buy” rating on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Dyne Therapeutics in a research note on Friday, July 17th. Finally, Cantor Fitzgerald assumed coverage on shares of Dyne Therapeutics in a research report on Thursday. They set an “overweight” rating for the company. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $34.17.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $24.44 on Monday. The business’s fifty day moving average price is $20.38 and its 200 day moving average price is $18.62. The firm has a market capitalization of $4.56 billion, a PE ratio of -7.59 and a beta of 1.06. The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. Dyne Therapeutics, Inc. has a 1-year low of $8.88 and a 1-year high of $25.00.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the company posted ($1.05) earnings per share. As a group, sell-side analysts forecast that Dyne Therapeutics, Inc. will post -3.01 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, CFO Erick Lucera sold 2,362 shares of the firm’s stock in a transaction dated Thursday, June 25th. The shares were sold at an average price of $20.37, for a total value of $48,113.94. Following the completion of the sale, the chief financial officer owned 121,563 shares in the company, valued at $2,476,238.31. This trade represents a 1.91% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Jason P. Rhodes sold 297,211 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $23.26, for a total transaction of $6,913,127.86. Following the sale, the director directly owned 2,962 shares in the company, valued at approximately $68,896.12. This represents a 99.01% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders purchased 9,000 shares of company stock worth $156,800 and sold 1,892,879 shares worth $40,500,030. Company insiders own 9.46% of the company’s stock.

Dyne Therapeutics Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.